NDA 200796 · Azurity
Edarbi
Azilsartan Kamedoxomil · Oral
NovelLast checked: Nov 19, 2026Latest source record: Jan 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Feb 25, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
3,052
2,180 serious, 256 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue azilsartan medoxomil as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue azilsartan medoxomil as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )
What it is approved for
From the label in effect Apr 20, 2026.
Azilsartan medoxomil is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with azilsartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood...
Mechanism: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the active moiety, azilsartan. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- EDARBI · AZILSARTAN KAMEDOXOMIL EQ 80MG MEDOXOMIL · TABLET, ORAL · Prescription · TE AB
- EDARBI · AZILSARTAN KAMEDOXOMIL EQ 40MG MEDOXOMIL · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Azilsartan Kamedoxomil" as an intervention, any sponsor and status, largest first.
- Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)Not yet recruiting
Gedeon Richter Plc.Industry
NCT06990204 · 56 participants (planned) · Start Jun 6, 2025 · Primary completion Jul 1, 2025
Drug: Azilsartan medoxomil 80 mg tablet; Edarbi® 80 mg tablets · For: Hypertension
Sites: Perm, Russia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea169
- hypertension165
- drug ineffective135
- dizziness132
- nausea131
- off label use115
- fatigue113
- headache106
- renal impairment100
- malaise99
- blood pressure increased97
- decreased appetite95
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 26 |
| 2012 | 43 |
| 2013 | 68 |
| 2014 | 54 |
| 2015 | 75 |
| 2016 | 166 |
| 2017 | 220 |
| 2018 | 152 |
| 2019 | 168 |
| 2020 | 196 |
| 2021 | 233 |
| 2022 | 386 |
| 2023 | 381 |
| 2024 | 333 |
| 2025 | 355 |
| 2026 | 196 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Edarbi (Azilsartan Medoxomil)
2024 spending
$36.7M
Beneficiaries
16,503
80,628 claims
Per beneficiary
$2,223
$8.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $32,535,198 |
| 2021 | $34,548,795 |
| 2022 | $36,008,755 |
| 2023 | $36,819,212 |
| 2024 | $36,680,945 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.
Baker WL, White WB · Ann Pharmacother 2011 · Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.